肝硬化肝细胞癌风险分层MRI监测前瞻性队列研究
研究前瞻性纳入86例肝硬化患者,根据基线钆塞酸增强MRI的LI-RADS风险分类,以3至36个月分层间隔进行3年HCC监测。结果显示13例诊断为HCC,无监测失败,检查次数较统一半年度策略减少44.2%。
要点
- 基线MRI为LR-4观察者HCC发生率高达73.4/100人年,应缩短复查间隔。
- 风险分层MRI监测10例(76.9%)在极早期检出HCC,利于根治性治疗。
- 分层策略较半年度超声/MRI统一方案减少44.2%检查次数,优化资源利用。
核心结论
- 使用钆塞酸增强MRI按风险分层间隔监测肝硬化患者,未发生监测失败,早期肿瘤检出率高,间期癌发生率低。
- 风险分层策略可在保持早期HCC检出的同时减少44.2%的检查频率,可能改善监测效率。
研究设计与样本
- 前瞻性队列研究,纳入2021年5月至2022年10月间86例肝硬化患者。
- 基线MRI按LI-RADS标准分为低风险、中风险及LR-4观察高风险类别,监测间隔为3至36个月。
- 全部患者接受钆塞酸增强MRI随访3年,主要结局为监测失败,定义为检出超出米兰标准的HCC。
关键影像表现/征象
- 基线的LI-RADS分类可区隔HCC发生风险,LR-4观察者发生率为73.4/100人年,低风险者为1.9/100人年。
- 13例HCC中10例(76.9%)在极早期被识别,1例(7.7%)为间期癌。
诊断标准与关键数值
- 低风险类别的HCC发生率为1.9/100人年。
- LR-4观察类别的HCC发生率为73.4/100人年。
- 监测失败率为0%(95%CI:0-24.7%)。
- 间期癌发生率为7.7%(1/13)。
临床应用与阅片要点
- 对肝硬化患者行基线钆塞酸增强MRI,可按LI-RADS风险类别设定个体化监测间隔。
- LR-4观察者极可能进展为HCC,临床上应安排更高频次的增强MRI随访。
- 风险分层方案中极早期HCC检出率达76.9%,提示缩短高危层复查间隔有助于早期干预。
局限性
- 研究样本量为86例,HCC诊断仅13例。
- 原文未提及该研究是否为单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Current hepatocellular carcinoma (HCC) surveillance relies on semiannual ultrasonography, which has limited sensitivity for early-stage detection. We evaluated the effectiveness of HCC surveillance using gadoxetic acid-enhanced MRI at risk-stratified screening intervals in patients with cirrhosis.
MATERIALS AND METHODS: We prospectively enrolled 86 patients with cirrhosis between May 2021 and October 2022. All patients underwent HCC surveillance using gadoxetic acid-enhanced MRI for 3 years at risk-stratified screening intervals ranging from 3 to 36 months, according to the assigned risk category defined by LI-RADS criteria on baseline MRI (low, intermediate, and high risk with LI-RADS LR-3 or LR-4 observations). The primary outcome was surveillance failure, defined as the detection of HCC beyond the Milan criteria.
RESULTS: HCC was diagnosed in 13 patients during the study period. The HCC incidence differed markedly across the MRI risk categories, ranging from 1.9 per 100 person-years in patients with low risk to 73.4 per 100 person-years in those with LR-4 observations. The primary endpoint was met with no surveillance failures (0%; 95% CI: 0-24.7%). Ten cases (76.9%) were identified at a very early stage, and there was one interval cancer (7.7%). Compared to a uniform semiannual surveillance strategy, the risk-stratified approach reduced the number of surveillance examinations by 44.2%.
CONCLUSION: HCC surveillance using gadoxetic acid-enhanced MRI at risk-stratified screening intervals resulted in no surveillance failures, a high rate of early-stage tumor detection, and a low incidence of interval cancer. This approach may improve surveillance effectiveness while reducing examination frequency.
KEY POINTS: QuestionWhether risk-stratified surveillance intervals for gadoxetic acid-enhanced MRI can maintain early HCC detection while reducing examination burden in cirrhosis remains unknown. FindingsRisk-stratified MRI surveillance detected all 13 incident HCCs within Milan criteria, with zero surveillance failures and a 44.2% reduction in examinations. Clinical relevanceRisk-stratified gadoxetic acid-enhanced MRI surveillance enables personalized screening intervals based on imaging risk categories, maintaining early-stage HCC detection while substantially reducing examination frequency in patients with cirrhosis.
引用
- Song, Jeong, Goh, et al. Risk-stratified MRI surveillance for hepatocellular carcinoma in cirrhosis: a prospective cohort study. Eur Radiol. 2026. PMID: 42603173. doi:10.1007/s00330-026-12820-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。